# Atorvastatin Therapy to Improve Endothelial Function in Sickle Cell Disease

> **NCT00072826** · PHASE1 · COMPLETED · sponsor: **National Institutes of Health Clinical Center (CC)** · enrollment: 44 (actual)

## Conditions studied

- Sickle Cell Disease

## Interventions

- **DRUG:** Oxypurinol
- **DRUG:** L-NMMA
- **DRUG:** Acetylcholine

## Key facts

- **NCT ID:** NCT00072826
- **Lead sponsor:** National Institutes of Health Clinical Center (CC)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-11-04
- **Primary completion:** 2007-08-24
- **Final completion:** 2007-08-24
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2019-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00072826

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00072826, "Atorvastatin Therapy to Improve Endothelial Function in Sickle Cell Disease". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT00072826. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*